Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525483 | 0.80 | CYP1A2 (0.44) | CYP1A2CYP2C19 | |
| SCHEMBL16960672 | 0.80 | CYP1A2 (0.33) | CYP1A2CYP2C19 | |
| SCHEMBL6821620 | 0.76 | CYP3A4 (0.33) | CYP2C19 | |
| SCHEMBL2094870 | 0.73 | HSP90AA1 (0.32) | — | |
| SCHEMBL3130927 | 0.73 | CYP3A4 (0.43) | — | |
| SCHEMBL5164132 | 0.72 | HPGD (0.38) | — | |
| SCHEMBL1877379 | 0.72 | RAB9A (0.38) | CYP1A2CYP2C19 | |
| SCHEMBL15124560 | 0.72 | PTGDR2 (0.35) | CYP1A2NOTUM | |
| SCHEMBL3892471 | 0.72 | — | — | |
| SCHEMBL12732927 | 0.72 | ALOX15 (0.42) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | claimed |
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | claimed |
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-09-17 | — | — | US | claimed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | claimed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | claimed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | claimed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | claimed |
| WO-2009003009-A1 | SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009003009-A1 | SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1440070-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2004060889-A1 | 5-THIAZOLE SUBSTITUTED 2-PYRROLIDINE-CARBOXYLIC ACIDS | GLAXO GROUP LIMITED (GB) | 2004-07-22 | — | — | WO | disclosed |
| WO-2003037894-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ZC3HAV1, EIF2AK2, POLRMT | CYP1A2 394/4885CYP2C19 371/4885NOTUM 917/4885 |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | EIF2AK2, RNGTT, POLR2E | CYP1A2 281/4885CYP2C19 260/4885NOTUM 601/4885 |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, NSUN2, RNMT | CYP1A2 734/4885CYP2C19 894/4885NOTUM 1160/4885 |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ZC3HAV1, HAVCR2, HCCS | CYP1A2 767/4885CYP2C19 611/4885NOTUM 1818/4885 |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | POLRMT, EIF2AK2, NSUN2 | CYP1A2 359/4885CYP2C19 436/4885NOTUM 624/4885 |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, ZC3HAV1, POLRMT | CYP1A2 484/4885CYP2C19 775/4885NOTUM 752/4885 |
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | HAVCR2, EIF2AK2, HCCS | CYP1A2 140/4885CYP2C19 116/4885NOTUM 1488/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | CYP1A2 385/4885CYP2C19 465/4885NOTUM 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.